Subgroup analysis for assessment of application of GABAergic cell on hyperalgesia improvement in 11 experiments
| Subgroup | No. of experiment |
Effect size | Heterogeneity ( |
Meta-regression | ||
|---|---|---|---|---|---|---|
| SMD (95% CI) | Coef. (95% CI) | |||||
| Species | ||||||
| Mice | 2 | 0.29 (–9.24 to 9.81) | 0.768 | 75.5% (0.043) | Ref. | |
| Rat | 9 | 1.56 (0.32 to 2.78) | 0.019 | 81.9% (< 0.001) | 1.23 (–1.36, 3.82) | 0.312 |
| Origin of pain | ||||||
| Peripheral | 10 | 0.97 (0.13 to 1.81) | 0.028 | 65.4% (< 0.001) | NA | NA |
| Central | 1 | NA | NA | NA | NA | NA |
| Route of transplantation | ||||||
| Intraspinal | 7 | 0.63 (0.08 to 1.17) | 0.030 | 40.2% (0.137) | Ref. | |
| Intrathecal | 4 | 3.08 (–0.38 to 6.55) | 0.066 | 83.8% (< 0.001) | 1.94 (0.17, 3.72) | 0.035 |
| Intracranial | 0 | NA | NA | NA | NA | NA |
| Cell source | ||||||
| Intrinsic GABAergic |
2 | 0.29 (–9.24 to 9.81) | 0.768 | 75.5% (0.043) | Ref. | |
| Genetically modified | 9 | 1.56 (0.32 to 2.78) | 0.019 | 81.9% (< 0.001) | 1.23 (–1.36, 3.82) | 0.312 |
| Stem cell derived | 0 | NA | NA | NA | NA | NA |
| Immunosuppressive | ||||||
| Yes | 4 | 3.33 (–0.38 to 6.55) | 0.066 | 83.8% (< 0.001) | Ref. | |
| No | 7 | 0.63 (0.08 to 1.17) | 0.030 | 40.2% (0.137) | –1.94 (–3.72, –0.17) | 0.035 |
| Antibiotic | ||||||
| Yes | 3 | 3.94 (–0.25 to 8.12) | 0.056 | 59.5% (0.082) | Ref. | |
| No | 8 | 0.64 (0.18 to 1.10) | 0.013 | 33.0% (0.198) | –2.97 (–4.57, –1.37) | 0.002 |
| Blinding of outcome assessor | ||||||
| Yes | 9 | 1.50 (0.10 to 2.89) | 0.039 | 86.8% (< 0.001) | Ref. | |
| No | 2 | 0.99 (–1.14 to 3.11) | 0.107 | 0.0% (0.588) | –0.49 (–3.28, 2.31) | 0.702 |
| Type of graft | ||||||
| Allograft | 7 | 0.63 (0.08 to 1.17) | 0.030 | 40.2% (0.138) | Ref. | |
| Xenograft | 4 | 3.08 (–0.38 to 6.55) | 0.066 | 83.8% (< 0.001) | 1.94 (0.17, 3.72) | 0.035 |
| Injury to transplant | ||||||
| 0 to 7 days | 7 | 0.63 (0.08 to 1.17) | 0.030 | 40.2% (0.138) | Ref. | |
| 8 days and over | 4 | 3.08 (–0.38 to 6.55) | 0.066 | 83.8% (< 0.001) | 1.94 (0.17, 3.72) | 0.035 |
| No. of cell (cell/kg) | ||||||
| ≤ 5 × 105 | 6 | 0.52 (–0.11 to 1.14) | 0.087 | 35.7% (0.183) | Ref. | |
| 5 × 105 to 1 × 106 | 5 | 2.54 (0.04 to 5.14) | 0.048 | 87.6% (< 0.001) | 1.62 (–0.12, 3.37) | 0.065 |
| Follow up duration | ||||||
| 4 to 7 weeks | 7 | 0.55 (0.03 to 1.06) | 0.041 | 28.2% (0.246) | Ref. | |
| 8 weeks and over | 4 | 3.14 (–0.10 to 6.38) | 0.054 | 82.9% (< 0.001) | 2.00 (0.36, 3.63) | 0.022 |
SMD: standardized mean difference, CI: confidence interval, Coef.: coefficient, NA: not applicable, Ref: reference category.
aSince, some included studies had more than one experiment, the number of experiments exceeded the number of studies. bGABAergic cells derived from the medial ganglionic eminence.